ResCure / ProgenaBiome - LARVOL DELTA

FACTORS ASSOCIATED WITH THE NEED FOR RESCURE LATERAL MYOTOMY DURING POEM (DDW 2025) - "Pre-POEM baseline DI <1.0 is a predictor of incomplete initial myotomy in POEM and highlights importance of intra-procedural physiologic assessment. DI alone and the combination of baseline ES and baseline DI are strongly associated with the need for RLM. The next steps would be to apply this equation to a prospective cohort to determine its efficacy in predicting the need for LRM as well as evaluating if there is clinical success at a DI<2.8."

Gastrointestinal Disorder • Rare Diseases

Comparison of Hepatocellular Carcinoma Prediction Models in Compensated Cirrhotic Patients with Chronic Hepatitis B Treated with Long-Term Nucleos(t)ide Analogue Therapy (APASL 2023) - "Objectives: We investigated the predictive performance of HCC risk in this cohort through AFDA model, and the other 7 prediction models of HCC, including aMAP, PAGE-B, CAMD, THRI, PAGE-B, AASL-HCC, HCC-RESCURE because their essential components of models are all baseline characteristic and blood tests. We enrolled 1158 nucleos(t)ide analogue-naïve, compensated cirrhotic patients with chronic hepatitis b (CHB) treated with entecavir or tenofovir from 2008 to 2018... AFDA model demonstrated higher ability than the other prediction models to stratify the risk of HCC and assess the low-risk group in compensated cirrhotic patients with CHB receiving NA therapy. 773"

Clinical • Diabetes • Gastrointestinal Cancer • Hepatitis B • Hepatocellular Cancer • Hepatology • Infectious Disease • Metabolic Disorders • Oncology • Solid Tumor • AFP

A Study of ResCure™ to Treat COVID-19 Infection (clinicaltrials.gov) - P1; N=0; Withdrawn; Sponsor: ProgenaBiome; N=50 ➔ 0; Initiation date: Jul 2020 ➔ Jan 2020; Not yet recruiting ➔ Withdrawn

Enrollment change • Trial initiation date • Trial withdrawal • Infectious Disease • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases